Tevogen Bio Holdings Inc. Files Form 8-K: Key Highlights for Investors

Overview

Tevogen Bio Holdings Inc. has filed a Form 8-K Current Report with the U.S. Securities and Exchange Commission (SEC), dated March 20, 2026. The filing is a standard procedural document required for significant events that may be of interest to shareholders and investors.

Key Points in the Report

• Filing Type: Form 8-K (Current Report)
• Date of Report: March 20, 2026
• Company Name: Tevogen Bio Holdings Inc.
• Trading Symbols:
  • Common Stock: TVGN
  • Warrants: TVGNW
• Exchange: Nasdaq Stock Market LLC
• Class of Securities Registered:
  • Common Stock: Par value \$0.0001 per share
  • Warrants: Each exercisable for one share of Common Stock at \$11.50 per share
• Emerging Growth Company: Yes (Tevogen Bio Holdings Inc. qualifies as an emerging growth company)
• Extended Transition Period for Complying with New or Revised Accounting Standards: The company has not elected to use the extended transition period.
• No Simultaneous Satisfying Filings: The company indicated that the 8-K is not being used to satisfy written communications under Rule 425, soliciting material under Rule 14a-12, or pre-commencement communications under Rules 14d-2(b) or 13e-4(c).
• File Number: 001-41002

Details for Shareholders

• No Price-Sensitive Events Disclosed:
  
  The Form 8-K filed does not disclose any new material events, transactions, or developments that would be considered price sensitive or likely to impact the company’s share price. There is no mention of mergers, acquisitions, leadership changes, financial restatements, or any other significant corporate actions.
• Standard Regulatory Filing:
  
  The report is a routine regulatory filing fulfilling SEC requirements. The company confirms its securities remain listed and active on Nasdaq, with ticker symbols TVGN (Common Stock) and TVGNW (Warrants).
• Emerging Growth Company Status:
  
  The confirmation of Tevogen’s status as an emerging growth company may provide certain regulatory and reporting advantages. However, no new information or changes regarding this status are disclosed.
• No Changes in Company Name or Address:
  
  The company’s name and address remain unchanged from prior filings.

Summary for Investors

There are no material events or disclosures in this Form 8-K filing that are likely to impact the share price of Tevogen Bio Holdings Inc. at this time. The filing is primarily administrative and does not provide new information that would be considered newsworthy or price sensitive for current or prospective investors.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should not rely solely on this summary and should consult the full SEC filing and their financial advisor for a comprehensive understanding of any reporting or disclosures. No new material events or price-sensitive information were disclosed in this filing.

View Tevogen Bio Holdings Inc. Historical chart here